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Abstract
This paper presents a summary of reported cases of Serious Adverse Events (SAEs) following
treatment with Mectizan® (ivermectin, Merck, Sharpe & Dohme) in onchocerciasis mass treatment
programs from January 1, 1989 to December 31, 2001 through a passive surveillance system. A
total of 207 SAE cases were reported out of approximately 165 million reported treatments
delivered during the period under review, giving rise to a cumulative incidence of 1 reported SAE
per 800,000 reported treatments. The mean age was 40 years and 70% of the cases were males.
The mean time between ivermectin intake and onset of illness was 1 day. For 57% of the cases (n
= 118), that was their first exposure to ivermectin. The majority of cases were reported from
Cameroon (n = 176; 85%) with peaks in the incidence of SAE reporting in 1989–1991 and 1994–
1995 when the program expanded to ivermectin-naïve populations. Fifty-five percent of the cases
from Cameroon (i.e. 97 out of 176 cases) were encephalopathic and were reported from the
central-southern region of the country; two-thirds of these cases were 'probable' or 'possible' cases
of Loa loa encephalopathy temporally related to ivermectin treatment. Reporting bias may explain
some but not all of the differences in SAE reporting between the 34 onchocerciasis-endemic
countries that have, or have had, mass treatment programs. Further research is needed to
understand the apparent clustering of encephalopathy cases in central-southern Cameroon since
L. loa infection alone probably does not explain the increased incidence of this type of SAE from
this region.
Introduction
The Mectizan® Donation Program (MDP) was established
in 1988 to provide medical, technical and administrative
oversight for the donation of Mectizan®  (ivermectin,
Merck Sharpe & Dohme) by Merck & Co., Inc. for the con-
trol of onchocerciasis worldwide. From 1989 to the end of
2001, approximately 165 million ivermectin treatments
were reported as having been administered in onchocer-
ciasis mass treatment programs in Africa, Latin America
and Yemen (MDP, unpublished data). Minor adverse
drug events such as fever, headache, pruritus, lymphaden-
opathy and myalgia are usually associated with the rapid
death of the microfilariae of Onchocerca volvulus and typi-
cally occur upon first exposure to the ivermectin [1].
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Serious Adverse Events (SAEs) were found to occur rarely
in large clinical and community trials of ivermectin con-
ducted in West Africa in the 1980s [1–3].
A passive surveillance system for SAEs following ivermec-
tin treatment is required of all onchocerciasis mass
treatment programs. The regulatory definition of SAEs
(See note 1) as well as SAE reporting forms, is provided by
MDP to the program managers at the time of initial appli-
cation for ivermectin. Program managers are required to
promptly report any SAEs temporally related to ivermec-
tin treatment to the MDP or Merck when they occur. Fur-
thermore, as part of the treatment report that program
managers submit to the MDP annually, they are asked to
report any SAEs that may have occurred during the previ-
ous treatment cycle. This review paper represents a sum-
mary of all the SAE cases reported to the MDP as having
occurred since the implementation of onchocerciasis
mass treatment programs in 1989 to the end of the calen-
dar year of 2001.
Global overview
As of August 31, 2002 a total of 207 SAE cases following
treatment with ivermectin had been reported to the MDP
as having occurred within the context of onchocerciasis
mass treatment programs from January 1, 1989 to Decem-
ber 31, 2001, primarily through the passive surveillance
system described above. This corresponds to a cumulative
incidence of approximately 1 reported SAE per 800,000
reported treatments delivered for the 13-year period
under review. Figure 1 illustrates the number of cases
reported to have occurred annually since 1989. Approxi-
mately 70% of the cases (n = 146) were male and the
mean age was 39.7 years (95% CI: 37.2, 42.2). The age dis-
tribution of the cases is shown in Table 1.
For more than half of the cases (n = 118; 57%), the SAE
occurred following their first exposure to ivermectin. The
mean time from ivermectin treatment to onset of symp-
toms was 2.2 days (95% CI: 1.8, 2.5) and the mean time
from onset of symptoms to seeking medical help or com-
ing to medical attention was 3.9 days (95% CI: 2.1, 5.8).
The 10 most frequent initial symptoms and signs reported
Annual frequency of SAEs reported to have occurred following ivermectin mass treatment from 1989 to 2001* Figure 1
Annual frequency of SAEs reported to have occurred following ivermectin mass treatment from 1989 to 2001* *cases 
reported as of August 31, 2002
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Table 1: Age distribution of SAE cases reported to have occurred 
following ivermectin mass treatment from 1989 to 2001*
Age group in years No. of cases† (% of total)
< 15 25 (12.5)
>= 15 < 30 55 (27.6)
>= 30 < 45 56 (28.1)
>= 45 < 60 36 (18.1)
>= 60 27 (13.6)
Total 199 (100)
*cases reported as of August 31, 2002; †the ages of 8 cases remain 
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are presented in Table 2. Of the cases with altered mental
status when first encountered by a clinician (n = 106), 52
were confused, obtunded or lethargic while 16 presented
with stupor and 38 presented in frank coma.
Once an SAE was reported to the MDP, a presumptive
diagnostic categorization was systematically applied,
based on information available in the SAE reports and
medical records (see Table 3). For these 207 reported SAE
cases, the diagnostic breakdown is shown in Table 4. The
treatments administered to these patients were primarily
supportive, the most common of which was intravenous
fluids (IVF). Table 5 illustrates the frequency of use of IVF
and other therapeutic interventions. The duration of spe-
cific treatment regimens was rarely reported except for
steroid use where 19 reports provided this information.
The longest duration of steroid use was 15 days and the
mean duration was 4.4 days (95% CI: 2.6, 6.3). A total of
113 out of the 207 reported SAE cases (55%) were
reported as being hospitalized; the length of hospital stay
varied widely from 0 to 241 days with a mean of 14.5 days
(95% CI: 9.6, 19.4).
The clinical outcome of the SAE cases was documented for
137 of the 207 total cases (66%). As shown in Table 6, for
those whose outcome is known, the majority of cases
recovered fully. There were a total of 28 deaths, corre-
sponding to a cumulative case-fatality rate of 20.4% if
Table 2: Presenting symptoms and signs of SAE cases reported to have occurred following ivermectin mass treatment from 1989 to 
2001*
Nature of Symptoms Frequency of occurrence† (%) Nature of Signs Frequency of occurrence† (%)
Difficulty or inability to stand or walk 60 (29.0) Altered Mental Status 106 (51.2)
Feverishness 54 (26.1) Fever (documented) 51 (24.6)
Headache 52 (25.1) Incontinence (urinary and/or fecal) 42 (20.3)
General myalgia or arthralgia 51 (24.6) Dysarthria 26 (12.6)
Fatigue/Asthenia 40 (19.3) Subconjunctival hemorrhage 26 (12.6)
Diarrhea 33 (15.9) Rash and/or urticuria 23 (11.1)
Vertigo 31 (15.0) Generalized edema 16 (7.7)
Dyspnea 22 (10.6) Extremity edema 16 (7.7)
Pruritis 20 (9.7) Facial edema 15 (7.3)
Nausea or vomiting 19 (9.1) Hypotension (documented) 13 (6.3)
*cases reported as of August 31, 2002; †total of individual percentages is greater than 100 because most patients presented with multiple symptoms 
and signs.
Table 3: Presumptive diagnostic categories assigned to reported SAE cases following Mectizan® treatment*
Diagnostic Category Symptoms & Signs
Anaphylactic Reaction Generalized immediate hypersensitivity response (urticaria, pruritis, angioedema, vascular collapse, life-threatening 
respiratory distress) after the administration of Mectizan®
Mild Mazzotti Reaction† Manifestation of 2 or more of the following symptoms within 7 days of the administration of Mectizan®: pruritis, 
fever, headache, edema, lymphadenopathy, myalgia, generalized body aches
Severe Mazzotti Reaction† Manifestation of 1 or both of the following symptoms within 7 days of the administration of Mectizan®: 
hypotension, asthma attacks in known patients; or manifestation of bullous skin lesions after 1–2 weeks of 
administration of Mectizan®
Functional Impairment with 
Normal Mental Status‡
Manifestation of symptoms typical of Mild Mazzotti Reaction at a severity such that patient required assistance with 
Activities of Daily Living (ADLs) (eating, bathing, walking) but maintained normal mental status within 7 days of the 
administration of Mecizan
Neurologic Encephalopathy, meningitis, or other neurologic sequelae within 7 days of the administration of Mectizan®
Cardiovascular Cardiovascular symptoms and signs, excluding hypotension, within 7 days of the administration of Mectizan®
Pulmonary Respiratory symptoms and signs, excluding Mazzotti-type bronchoconstriction, within 7 days of the administration 
of Mectizan®
Gastrointestinal Gastrointestinal symptoms including dehydration within 7 days of the administration of Mectizan®
Other Any other symptoms and signs within 7 days of the administration of Mectizan®
*All cases met the definition of an SAE (See note 1) before being assigned one of these presumptive diagnoses; †adapted from McGavin DDM 
(1998). Opthalmology in the Tropics and Subtropics. In Manson's Tropical Diseases. 20th edn. (ed. GC Cook GC) W. B. Saunders Co. Ltd, London, p. 
248; ‡adapted from Gardon J et al. [6].Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S3
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only the cases where outcome is known are included in
the analysis (n = 137). If all cases where outcomes are
unknown are considered to have survived, this rate
decreases to 13.5% of the 207 total reported SAE cases for
the period under review.
The cause of death was difficult to determine in most cases
due to the paucity of diagnostic information documented
in the SAE reports and the medical records. Inpatient
complications such as infected decubitus ulcers, and/or
hypoglycemia and/or dehydration were antecedents to
death in 12 of these 28 patients. In 3 other cases, patients
were temporarily taken out of the hospital by family
members, against medical advice, to seek the help of tra-
ditional healers, and later returned to the hospital before
they ultimately died. In addition, an 11-year old boy that
died was administered ivermectin despite overt contrain-
dications to treatment; an undiagnosed acute illness
severe enough to prevent him from going to school the
morning before taking treatment. Scenarios such as these
present challenging confounding factors that preclude
determination of the actual cause of death.
Geographical distribution
Out of the 34 onchocerciasis endemic countries that have
had, or currently have, ivermectin mass distribution, SAEs
had been reported by only 7 during the period under
review (see Figure 2). Eighty-five percent of the SAE cases
were reported from Cameroon: 176 out of 207 (see Figure
3). Yet less than 5% of ivermectin treatments worldwide
have been administered in Cameroon (MDP, unpub-
lished data). The number of cases reported from Cam-
eroon is compared, on an annual basis, to the 6 other
countries that have ever reported SAEs from 1989 to 2001
in Figure 4. Since annual treatment figures are difficult to
quantify, cumulative incidence rates over 2 to 3 year time-
Table 4: Presumptive diagnoses of SAE cases reported to have occurred following ivermectin mass treatment from 1989 to 2001*
Presumptive Diagnosis† No. of cases within diagnostic 
category (% of total no. of cases)
Neurologic impairment 110 (53.1)
Mild Mazzotti reaction 43 (20.8)
Other or insufficient information to assign presumptive diagnosis 22 (10.6)
Severe Mazzotti reaction 17 (8.2)
Functional impairment with normal mental status 6 (2.9)
Gastrointestinal illness 5 (2.4)
Anaphylactic reaction 3 (1.5)
Respiratory illness (except asthma attack in a known asthmatic which falls into the category of Severe 
Mazzotti reaction)
1 (0.5)
Cardiovascular illness (except hypotension which falls into the category of Severe Mazzotti reaction 0 (0)
Total 207 (100)
*cases reported as of August 31, 2002; †see Table 3 for definitions of presumptive diagnoses.
Table 5: Therapeutic interventions used in the management of 
SAE cases reported to have occurred following ivermectin mass 
treatment from 1989 to 2001*
Type of therapeutic 
intervention
Frequency of use (% use out 
of 207 total cases)†
Intravenous fluids 132 (63.8)
Corticosteroids 92 (44.4)
Analgesics/antipyretics 84 (40.6)
Antimalarials 76 (36.7)
Vitamin B complex 75 (36.2)
Antibiotics 51 (24.6)
Antihistamines 48 (23.2)
Multivitamins 30 (14.5)
*cases reported as of August 31, 2002; †total of individual percentages 
is greater than 100 because multiple treatments were administered 
per person in most cases.
Table 6: Known clinical outcomeof SAE cases reported to have 
occurred following ivermectin mass treatment from 1989 to 
2001*
Clinical Outcome Frequency of 
occurrence (%)
Full recovery 96 (70.1)
Full recovery (including neurologic) but 
other deficit persists
4† (2.9)
Partial neurologic deficit 9 (6.6)
Death 28 (20.4)
Total 137‡ (100)
*cases reported as of August 31, 2002; †there were 2 cases of 
scarring due to drug skin reaction, 1 case of permanent soft tissue 
damage due to severe decubitus ulcers, and 1 case of nephrotic 
syndrome which predated the SAE; ‡the clinical outcome was not 
documented in 70 cases.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S3
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periods for reported SAEs for the neighboring countries of
Cameroon, Central African Republic, Democratic Repub-
lic of Congo and Sudan are compared in Figure 5.
Focus on Cameroon
Seventy percent of the total caseload from Cameroon was
male and 61% were taking ivermectin for the first time.
The youngest individual affected was 6 years old and the
oldest was 89 years old. The mean age was 39.9 years
(95% CI: 37.2, 42.6). Peaks in SAE reporting in Cameroon
occurred during 1989–1991 and 1994–1995; the majority
of the cases reported during those time periods originated
primarily from areas of program expansion where the
population was generally naïve to ivermectin.
Ninety-seven out of the 176 reports were of encephalo-
pathic cases following ivermectin treatment. The first
encephalopathic case occurred in 1990 and the year of
peak reporting of encephalopathic cases was 1999 (n =
34). Table 7 compares the number and type of encephalo-
pathic cases from Cameroon to those reported from other
countries and Figure 6 illustrates the geographical distri-
bution of the encephalopathic cases that occurred in Cam-
eroon. As shown in Figure 2, all 97 Cameroonian
encephalopathic cases occurred in the Loa loa endemic
areas in the central-southern region of the country (Cen-
tral, Littoral, West and South Provinces). Of these, there
were 63 cases with sufficient L. loa laboratory data to sup-
port a diagnosis of 'probable' or 'possible' L. loa encepha-
lopathy following ivermectin treatment in the context of a
suggestive clinical description (See note 2) (see Table 7).
The most severely affected province was Central Province
which reported 53 out of the 63 (84%) 'probable' or
'possible' L. loa encephalopathy cases. Peak reporting was
from the District of Monatélé during the 1994–1995 treat-
ment cycle (n = 17) and from the District of Okola in the
1999 treatment cycle (n = 25). Both of these peaks coin-
cided with the first year of mass treatment in a population
that was generally naïve to ivermectin. Incidence figures
per district were generally impossible to calculate since
the annual report forms do not require projects to report
treatments administered at the district level.
Conclusions & Discussion
The main findings from this analysis of reported SAE cases
following ivermectin administration in onchocerciasis
mass treatment programs over a 13-year period, using a
passive surveillance system, are as follows:
1. Seventy percent of the cases were male;
2. More than one-half of the cases (56%) were between
the ages of 15 and 44;
3. In more than one-half of the cases (57%), the patient
was naïve to ivermectin;
4. Altered mental status was the predominant clinical
presentation reported in 51% of cases;
5. On average, symptoms began 2 days after treatment;
6. Patients came to medical attention approximately 4
days after the onset of symptoms;
Geographical distribution of all SAEs reported to have  occurred following mass treatment with ivermectin from  1989 to 2001 (as of August 31, 2002) Figure 2
Geographical distribution of all SAEs reported to have 
occurred following mass treatment with ivermectin from 
1989 to 2001 (as of August 31, 2002)
Proportion of SAEs reported to have occurred following  ivermectin mass treatment from 1989 to 2001*, by reporting  country Figure 3
Proportion of SAEs reported to have occurred following 
ivermectin mass treatment from 1989 to 2001*, by reporting 
country; *cases reported as of August 31, 2002; † all 
reported cases from Sudan are from the southern region; 
‡other reporting countries are Ethiopia (n = 1), Liberia (n = 
1) and Central African Republic (n = 1).
Others‡
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Annual frequency of SAEs reported to have occurred following ivermectin mass treatment from 1989 to 2001*, by reporting  country Figure 4
Annual frequency of SAEs reported to have occurred following ivermectin mass treatment from 1989 to 2001*, by reporting 
country; *cases reported as of August 31, 2002; †all reported cases from Sudan are from the southern region; ‡other reporting 
countries are Ethiopia (n = 1), Liberia (n = 1) and Central African Republic (n = 1).
Incidence of reported SAEs following ivermectin mass treatment from selected countries in Central Africa, 1989 to 2001* Figure 5
Incidence of reported SAEs following ivermectin mass treatment from selected countries in Central Africa, 1989 to 2001*; 
*cases reported as of August 31, 2002; † CAR=Central African Republic; DRC=Democratic Republic of Congo; ‡ all reported 
cases from Sudan are from the southern region.
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7. The most common therapeutic interventions adminis-
tered once the SAE developed were supportive;
8. Where clinical outcome is known (i.e. in approximately
two-thirds of the cases), 70% recovered fully and 20%
died.
9. Eighty-five percent of SAE cases were reported from
Cameroon with peak reporting coinciding with program
expansion into ivermectin-naïve areas; similar observa-
tions were not been reported from other countries.
10. Approximately 50% of the reported cases were
encephalopathic illnesses, of which 94% were reported
from Cameroon.
11. All the encephalopathic cases from Cameroon were
reported from the central-southern region of the country;
two-thirds of which were presumed to be associated with
high intensity L. loa infection.
When all 34 onchocerciasis-endemic countries are consid-
ered together, the incidence of reported SAEs following
ivermectin treatment appears to be low: approximately 1
case per 800,000 treatments. However, when Cameroon
is considered separately the incidence of reported SAEs in
general, and reported encephalopathic SAEs associated
with L. loa in particular, are much higher. This difference
is even more striking when Cameroon is compared to
other L. loa endemic countries of Central Africa that also
conduct mass treatment of onchocerciasis with
ivermectin.
Some areas in the central-southern region of Cameroon,
where the L. loa encephalopathy cases in this study pre-
dominate, have been shown to have L. loa prevalences as
high as 20% [4]. Although detailed observed loiasis
prevalence data is limited for other African countries, a
map of predicted loiasis prevalence using Geographic
Information Systems (GIS) and remote sensing
technologies suggests that other countries in Central
Africa have prevalences as high as those observed and pre-
dicted in Cameroon [8]. Since individuals with high L. loa
microfilaremia have been demonstrated to have an
increased risk of developing an encephalopathic illness
following ivermectin treatment [5,6] and a strong correla-
tion has been found between the prevalence of loiasis and
the prevalence of individuals with high intensity L. loa
microfilaremia (> 30,000 microfilariae per milliliter of
peripheral blood) [7], one would expect similar rates of
reporting of post-treatment L. loa encephalopathy from
other Central African countries if intensity of L. loa infec-
tion was the most important risk factor for developing
encephalopathy following treatment with ivermectin.
Three primary phenomena may explain this differential
reporting of SAEs (encephalopathic or otherwise): 1)
reporting bias; 2) as yet unidentified confounding factors
in central-southern Cameroon which increase individual
vulnerability to ivermectin; and 3) genetic variations in
the strains of L. loa and/or its vector, Chrysops spp. which
make the local species more virulent or neuropathic in
this region of Cameroon.
There may be under-reporting of SAE cases from countries
other than Cameroon. The SAE database of the MDP is
based almost exclusively on reports received from
clinicians and program participants through a passive sur-
veillance system (there were 7 documented cases
abstracted from prospective studies conducted by
researchers in Cameroon in the context of ivermectin
clinical studies or mass treatment programs [5,6,9] that
have been included in this analysis). Thus, it is difficult to
be certain that the reported number of cases represents the
actual number of cases that occurred in the field. In the
case of very severe clinical conditions such as encephalop-
athy it is likely that those cases will come to the attention
of community leaders and health workers locally, and
thus would likely be reported to national-level staff who
would then report them to the MDP. However, in the case
of less severe clinical conditions which may still be seri-
ous, as defined from a regulatory perspective (See note 1),
and thus qualify as an SAE, it is possible that some degree
of under-reporting may exist.
Table 7: Reported encephalopathic cases following ivermectin mass treatment from 1989 to 2001*
Type of Encephalopathy No. of cases from Cameroon No. of cases from other countries Total no. of cases
Probable L. loa encephalopathy† 33 0 33
Possible L. loa encephalopathy† 30 2§ 32
Encephalopathy of other known etiology 1‡ 0 1
Encephalopathy of unknown etiology 33 4|| 37
Total 97 6 103
*cases reported as of August 31, 2002; †See note 2 for definitions; ‡case of cerebral malaria; §Central African Republic = 1 case; Sudan (southern) 
= 1 case; ||Democratic Republic of Congo = 2 cases; Sudan (southern) = 1 case; Nigeria = 1 case.Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S3
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Conversely, there may be over-reporting of SAEs in gen-
eral from Cameroon, particularly in recent years.
Increased awareness and sensitization of the population
and healthcare workers after the cluster of encephalo-
pathic SAEs in Cameroon in 1999, has most likely
improved the quality of their surveillance system. How-
ever, it may also have had an untoward effect in subse-
quent years. For example, 72% of the 47 SAE cases
reported in 1999 were encephalopathic whereas in 2001,
52 SAE cases were reported of which 33% were encepha-
lopathic in nature while almost 50% were categorized by
MDP as mild Mazzotti reactions.
In addition, the passive surveillance system for SAEs is of
varying quality and completeness in different countries;
this may explain some of the observed variation in SAE
cases reported from the 34 countries which have, or have
had, mass treatment programs. Furthermore, even when
the SAE forms are submitted, they are sometimes incom-
plete. Therefore the assignment of presumptive diagnoses
was sometimes based on limited clinical and laboratory
data which may have introduced a misclassification error.
The MDP is currently in the process of trying to improve
both the quality and completeness of the SAE reporting
system.
Reporting bias may account for some of the quantitative
and qualitative differences in reporting but would not be
expected to explain all of the qualitative differences in the
types of illnesses reported from the different countries fol-
lowing treatment with ivermectin. It certainly does not
explain the seriousness of the problem in Cameroon,
especially not in Central Province from where the major-
ity of the L. loa associated encephalopathic cases have
been reported.
It is important to note that not all individuals heavily
infected with L. loa develop encephalopathy following
ivermectin treatment. Thus, there is an urgent need to
investigate other individual risk factors that may work
alone or synergistically with high intensity L. loa micro-
filaremia to increase vulnerability to developing an
encephalopathy following ivermectin treatment. Poten-
tial candidates may be human genetic differences in
metabolism and/or the blood-brain barrier, and
interactions with other pharmaceutical agents, herbal
preparations or alcoholic beverages that may be ingested
at the same time as ivermectin.
Genetic differences in the local strains of L. loa and/or the
Chrysops vector and any association that these differences
may have with virulence and pathogenesis, may also
explain the apparent clustering of cases of L. loa encepha-
lopathy temporally related to ivermectin treatment in
Central Province.
Finally, factors pertaining to the community and the local
health system such as effectiveness of surveillance and
evacuation system in the community, distance from a
health facility, presence of a functioning referral system
from primary to tertiary health facilities, availability of
supportive therapy, presence of staff trained on SAE man-
agement and hospital discharge policies will need to be
assessed and strengthened as they may significantly
impact the clinical outcome once the SAE develops.
Following the increased number of encephalopathic SAE
cases reported from Cameroon in 1999, the Mectizan®
Expert Committee (the technical advisory body that over-
sees the use of Mectizan®, the donated form of ivermectin)
and the Technical Consultative Committee of the African
Programme for Onchocerciasis Control (the technical
advisory body that oversees the implementation of com-
munity-directed treatment with Mectizan®  in most of
Africa) implemented new recommendations for ivermec-
tin mass treatment strategies in L. loa endemic areas to
reduce the risk of death and disability in the rare event
that a case of L. loa encephalopathy occurs following treat-
ment. Specifically, in areas where the population is naïve
to ivermectin, and/or there have been fewer than 2 annual
ivermectin treatments, and/or less than 60% therapeutic
coverage of the community in previous treatment rounds,
and/or where there have been cases of post-treatment
encephalopathy, it is recommended that refined
epidemiologic criteria are applied before a given commu-
nity is included in an onchocerciasis mass treatment pro-
gram with ivermectin. In addition, an intensified system
of health education, SAE surveillance, referral and clinical
management needs to be put in place before mass treat-
ment may begin. These measures are designed to reduce
poor clinical outcome even if they are not able to reduce
the risk of the event occurring. However, the individual
risk of developing an SAE, including post-treatment L. loa
encephalopathy, dramatically decreases after sequential
annual doses of ivermectin due to the strong reduction of
the microfilariae of both O. volvulus and L. loa [1,10,11],
the chemotactic behavior and death of which are pre-
sumed to trigger the symptoms and signs experienced by
the patient [1,5,6]. In fact, in the case of post-treatment L.
loa encephalopathy there were only 2 out of the 65 total
reported cases (3%) in which the individual had report-
edly taken ivermectin in the previous 12 months. Thus, if
ivermectin treatment is administered annually at high lev-
els of coverage (both therapeutically and geographically)
then the occurrence of all SAEs should be reduced to neg-
ligible levels, allowing the benefits of treating onchocer-
ciasis to be more fully appreciated in affected
communities.
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Note 1
A Serious Adverse Event is defined as follows:
"an adverse experience following treatment with a drug
that results in any of the following:
• death
• life-threatening adverse drug experience
• in-patient hospitalization or prolongation of an existing
hospitalization
• persistent or significant disability/incapacity
• congenital anomaly or birth defect
• cancer
• overdose (accidental or intentional).
Important medical events that may not result in death, be
life-threatening, or require hospitalization may be consid-
ered a serious adverse drug experience when, based upon
appropriate medical judgment, they may jeopardize the
patient or subject, and may require medical or surgical
intervention to prevent one of the outcomes listed in the
definition above: such events should also be reported."
(Merck & Co., Inc., adapted from the definitions of the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use)
Note 2
The definitions of 'probable' and 'possible' cases of L. loa
encephalopathy following ivermectin treatment are as
follows:
Probable Case of L. loa Encephalopathy
• Encephalopathy (without seizures, usually with fever) in
a person previously healthy and has no other underlying
cause for encephalopathy, and
• Onset of progressive Central Nervous System (CNS)
symptoms and signs within 7 days of treatment with iver-
mectin; illness progressing to coma without remission,
and
• Peripheral blood L. loa > 10,000 microfilariae per mil-
liliter of peripheral blood (mf/ml) pre-treatment, or >
1,000 mf/ml within 1 month post-treatment, or > 2700
mf/ml within 6 months of treatment; and/or L. loa micro-
filariae present in cerebrospinal fluid (CSF).
Possible Case of L. loa Encephalopathy
• Encephalopathy (without seizures, usually with fever) in
a person previously healthy and has no other underlying
cause for encepahalopathy, and
• Onset of progressive CNS symptoms and signs within 7
days of treatment with ivermectin; illness progressing to
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• Semi-quantitative or non-quantitative (i.e. +, ++, +++)
positive L. loa microfilariae in peripheral blood within 1
month post-treatment.
These definitions are adapted from those originally put
forth by the independent experts that consulted for the
MDP in 1995, in the report "Central Nervous System
(CNS) Complications of Loiasis and Adverse CNS Events
following Treatment: Report of an invited consultation,
2–3 October 1995" (Atlanta, GA: Mectizan® Donation
Program, 1996).